98%
921
2 minutes
20
Background: Selection bias due to non- or incomplete compliance is challenging in surveys. Using data from a longitudinal survey in testicular cancer survivors (TCSs), we identify factors predicting incomplete compliance.
Method: In a questionnaire-based national survey (1998-2016; three waves) 1,813 > 5 year TCSs were invited to report post-treatment adverse health outcomes (AHOs). We separated complete from partial participants (participation in all three waves versus participation only once or twice). At each wave we additionally identified responders and non-responders based on their questionnaire return at the respective wave. Multivariable logistic regression analysis identified associations between AHOs reported at the first wave and partial participation. Survival differences between Responders and Non-Responders were assessed by the Kaplan-Meier estimate and the logrank test. Level of significance: p < 0.05.
Results: Of 1813 TCSs 1,346 TCSs (79 %) completed the first wave's questionnaire, and 783 (58 %) became complete and 653 (42 %) partial participants. Poor socio-economics, unhealthy life style, major co-morbidity and chemotherapy-related AHOs reported at the first survey wave were associated with a significant 1.5-1.9 times increased risk for partial participation. At the two last waves non-responders had significantly decreased overall survival compared with responders.
Conclusion: Our longitudinal study indicates positive selection bias during the 17 years of a longitudinal survey among TCSs, with fewer AHOs among Complete than among Partial Participants. If not sufficiently compensated for by data from external sources and/or statistical methods, attrition bias in longitudinal surveys may limit the external validity of findings related to cancer survivors' self-reported AHOs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.canep.2020.101744 | DOI Listing |
BMJ Open
September 2025
Medizinische Fakultät OWL, AG Allgemein- und Familienmedizin, Universität Bielefeld, Bielefeld, Germany
Introduction: Multimorbidity contributes significantly to poor population health outcomes while straining healthcare systems. Although some multimorbid patients experience an accelerated health decline (a decline in well-being or functional status that cannot be attributed to the natural ageing-related health deterioration), others can remain stable for years. Identifying risk factors for accelerated health decline in persons with multimorbidity could help prevent complications and reduce unnecessary interventions.
View Article and Find Full Text PDFClin Res Hepatol Gastroenterol
September 2025
Dr. D.Y. Patil Vidyapeeth (Deemed to be University), Pimpri, Pune, Maharashtra, India. Electronic address:
J Bras Pneumol
September 2025
. Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil.
Objective: Thymic tumors are a rare group of anterior mediastinal tumors. Surgery is the primary treatment. Adjuvant treatment is used in select cases.
View Article and Find Full Text PDFBioinformatics
September 2025
Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania United States.
Summary: Causal mediation analysis investigates the role of mediators in the relationship between exposure and outcome. In the analysis of omics or imaging data, mediators are often high-dimensional, presenting challenges such as multicollinearity and interpretability. Existing methods either compromise interpretability or fail to effectively prioritize mediators.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla.
Importance: Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammatory diseases (IMIDs). However, safety concerns have led to regulatory restrictions.
Objective: To compare the risk of adverse events with JAK inhibitors vs tumor necrosis factor (TNF) antagonists in patients with IMIDs in head-to-head comparative effectiveness studies.